Search results for "GATES"

showing 10 items of 176 documents

Targeting Alzheimer’s disease with multimodal polypeptide-based nanoconjugates

2021

LRP1-targeted St-Cl–polyglutamate conjugates as multivalent neuroprotective/neurotrophic therapeutics for Alzheimer’s disease.

Alzheimer’s disease (AD)Mice TransgenicNanoconjugatesHippocampal formationHippocampusNeuroprotectionAD treatmentMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAlzheimer DiseaseBisdemethoxycurcuminAnimalsOlfactory memoryResearch Articles030304 developmental biology0303 health sciencesAmyloid beta-PeptidesMultidisciplinaryPolyglutamatebiologySciAdv r-articlesLife Sciences3. Good healthOlfactory bulbDisease Models AnimalApplied Sciences and Engineeringchemistrybiology.proteinNeuroscience030217 neurology & neurosurgeryNanoconjugatesResearch ArticleNeurotrophinScience Advances
researchProduct

The sea urchin embryo: a model to study Alzheimer's beta amyloid induced toxicity.

2009

Abstract Alzheimer’s disease (AD) is the most common form of dementia. The cause of AD is closely related to the accumulation of amyloid beta peptide in the neuritic plaques. The use of animal model systems represents a good strategy to elucidate the molecular mechanism behind the development of this pathology. Here we use the Paracentrotus lividus embryo to identify molecules and pathways that can be involved in the degenerative process. As a first step, we identified the presence of an antigen related to the human APP, called Pl APP. This antigen, after gastrula stage, is processed producing a polypeptide of about 10 kDa. By immunohistochemistry we localized the Pl APP antigen in some ser…

AmyloidAmyloid betaBiophysicsApoptosisBiochemistryNervous SystemParacentrotus lividusAlzheimer Diseasebiology.animalAnimalsHumansSenile plaquesAntigensMolecular BiologySea urchinCaspaseTUNEL assayAmyloid beta-Peptidesbiologybiology.organism_classificationPeptide FragmentsRecombinant ProteinsCell biologyBiochemistryApoptosisCaspasesModels Animalbiology.proteinParacentrotusParacentrotus lividusAmyloid-betaOligomers Fibrillar aggregatesApoptosisAnimal modelArchives of biochemistry and biophysics
researchProduct

Polyaspartylhydrazide Copolymer-Based Supramolecular Vesicular Aggregates as Delivery Devices for Anticancer Drugs

2008

In this paper we report on three different hydrophilic copolymers based on alpha,beta-polyaspartylhydrazide (PAHy) bearing butyric groups in the side chain (C 4) (PAHy-C 4) or a combination of butyric groups and positive charged residues ((carboxypropyl)trimethylammonium chloride, CPTACl) (PAHy-C 4-CPTA) that were synthesized and used for the preparation of new supramolecular vesicular aggregates (SVAs) containing gemcitabine as an antitumor drug. Gemcitabine-loaded SVAs containing synthesized PAHy derivatives were characterized from the physicochemical and technological point of view and the in vitro toxicity and anticancer activity on two different human cancer cell lines, i.e., CaCo-2 (h…

Antimetabolites AntineoplasticMagnetic Resonance SpectroscopyPolymers and PlasticsPolymerssupramolecular aggregates polyaspartylhydrazide copolymersSupramolecular chemistryApoptosisBioengineeringDeoxycytidineBiomaterialsButyric acidchemistry.chemical_compoundDrug Delivery SystemsTumor Cells CulturedMaterials ChemistrySide chainCopolymerHumansThyroid NeoplasmsCytotoxicityCells CulturedChromatography High Pressure LiquidDrug CarriersMolecular StructureChemistryVesicleFlow CytometryGemcitabineIn vitroBiochemistryColonic NeoplasmsChromatography GelPeptidesDrug carrierBiomacromolecules
researchProduct

Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model.

2012

Abstract Supramolecular vesicular aggregates (SVAs), made up by self-assembling liposomes and polyasparthydrazide co-polymers conjugated to folic acid molecules were extensively investigated in this manuscript as potential active targeting formulation for anticancer drug delivery. Folate-targeted systems (FT-SVAs) were used to treat breast cancer and to further proof the potential in vivo administration of these systems for the therapeutic treatment for several aggressive solid tumors. The physicochemical and technological parameters of FT-SVAs are suitable for their potential in vivo administration. The chemotherapeutic activity of GEM-loaded FT-SVAs was increased during in vivo experiment…

Antimetabolites AntineoplasticStereochemistryPharmaceutical ScienceBreast NeoplasmsMice SCIDDeoxycytidinechemistry.chemical_compoundMiceBreast cancerDrug Delivery SystemsFolic AcidPharmacokineticsIn vivoMice Inbred NODPEG ratiomedicineAnimalsHumansLiposomeDrug CarriersGeneral Medicinemedicine.diseaseXenograft Model Antitumor AssaysGemcitabineGemcitabinePLGANylonsHydrazineschemistryDrug deliveryLiposomesCancer researchMCF-7 CellsFemaleFolate supramolecular vescicular aggregates anticancer treatmentBiotechnologymedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

2021

The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and brid…

BendamustineOncologymedicine.medical_specialtyCancer ResearchImmunoconjugatesMedizinSalvage therapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProgression-free survivalRetrospective StudiesSalvage TherapyLymphoid Neoplasiabusiness.industryAntibodies MonoclonalHematologyChemotherapy regimenPolatuzumab vedotinTransplantationRegimenbacteriaRituximabbusinessmedicine.drug
researchProduct

MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET

2017

International audience; Improved bifunctional chelating agents (BFC) are required for copper-64 radiolabelling of monoclonal antibodies (mAbs) under mild conditions to yield stable, target-specific imaging agents. Four different bifunctional chelating agents (BFC) were evaluated for Fab (Fragment antigen binding) conjugation and radiolabelling with copper-64. Two DOTA- (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and two NOTA- (1,4,7-triazacyclononane-1,4,7-triacetic acid) derivatives bearing a p-benzyl-isothiocyanate group were conjugated to Fab-trastuzumab - which targets the HER2/neu receptor - and the average number of chelators attached ranged from 2.4 to 4.3 macrocycles …

BiodistributionImmunoconjugatesmedicine.drug_class[SDV.CAN]Life Sciences [q-bio]/CancerMonoclonal antibody030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/CancerInorganic ChemistryHeterocyclic Compounds 1-RingImmunoglobulin Fab FragmentsMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumormedicineAnimalsHumansDOTA[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyTissue DistributionChelationBifunctionalChelating AgentsRadiochemistryMammary Neoplasms ExperimentalTrastuzumabIn vitroImmunoconjugateCopper RadioisotopesBiochemistrychemistryPositron-Emission Tomography030220 oncology & carcinogenesis[SDV.IMM]Life Sciences [q-bio]/ImmunologyCopper-64
researchProduct

Trehalose effects on α-crystallin aggregates

2007

alpha-Crystallin in its native state is a large, heterogeneous, low-molecular weight (LMW) aggregate that under certain conditions may progressively became part of insoluble high-molecular weight (HMW) systems. These systems are supposed to play a relevant role in eye lens opacification and vision impairment. In this paper, we report the effects of trehalose on alpha-crystallin aggregates. The role of trehalose in alpha-crystallin stress tolerance, chaperone activity and thermal stability is studied. The results show that trehalose stabilizes the alpha-crystallin native structure, inhibits alpha-crystallin aggregation, and disaggregates preformed LMW systems not affecting its chaperone acti…

BiophysicsMicroscopy Atomic ForceBiochemistrythermal stabilitychemistry.chemical_compoundCrystallinNative stateThermal stabilityBenzothiazolesalpha-Crystallinsalpha-crystallinChaperone activityProtein Structure QuaternaryEye lensMolecular BiologyNative structureCircular DichroismTrehalosefood and beveragesCell BiologyTrehaloseeye diseaseschaperone activityThiazolesSpectrometry FluorescencechemistryBiochemistryaggregatesα-Crystallin Trehalose Aggregates Chaperone activity Thermal stabilitysense organsBiochemical and Biophysical Research Communications
researchProduct

CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity.

2002

Interleukin-10 (IL-10)–treated dendritic cells (DCs) induce an alloantigen- or peptide-specific anergy in various CD4+ and CD8+ T-cell populations. In the present study, we analyzed whether these anergic T cells are able to regulate antigen-specific immunity. Coculture experiments revealed that alloantigen-specific anergic CD4+ and CD8+ T cells suppressed proliferation of syngeneic T cells in a dose-dependent manner. The same effect was observed when the hemagglutinin-specific CD4+T-cell clone HA1.7 or tyrosinase-specific CD8+ T cells were cocultured with anergic T cells of the same specificity. Anergic T cells did not induce an antigen-independent bystander inhibition. Suppression was depe…

CD4-Positive T-LymphocytesIsoantigensImmunoconjugatesImmunologyAntigen-Presenting Cellschemical and pharmacologic phenomenaBiologyCD8-Positive T-LymphocytesLymphocyte ActivationBiochemistryT-Lymphocytes RegulatoryAbataceptInterleukin 21Antigens CDAntigens NeoplasmCytotoxic T cellHumansCTLA-4 AntigenIL-2 receptorLeukapheresisAntigen-presenting cellMelanomaCells CulturedClonal AnergyImmunosuppression TherapyMonophenol MonooxygenaseCD28Cell BiologyHematologyDendritic cellT lymphocyteDendritic CellsNatural killer T cellAntigens DifferentiationCoculture TechniquesCell biologyInterleukin-10ImmunologyCD4 AntigensLeukocytes MononuclearCell DivisionBlood
researchProduct

PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery

2013

Abstract Salmon calcitonin (sCT) is characterized by a poor oral availability. A new copolymer, β-poly(N-2-hydroxyethyl)-graft-{N-2-ethylene[2-poly(methacrylic acid sodium salt)isobutyrate]}- d , l -aspartamide (PHEA-IB-p(MANa + )), was designed for the oral administration of sCT through the formation of supramolecular aggregates (SAs) based on electrostatic interactions. Several sCT/PHEA-IB-p(MANa + ) weight ratios were characterized by turbidimetry, DLS, zeta potential, and microscopy analysis. After the incubation of sCT/PHEA-IB-p(MANa + ) complex with digestive enzymes, 10% (w/w) of loaded sCT was released in the native form. In vitro investigation was carried out to determine the copol…

Calcitoninmedicine.medical_specialtypeptide deliveryAdministration OralPharmaceutical Sciencechemistry.chemical_elementPeptidePharmacologyCalciumRats Sprague-DawleyRandom AllocationDrug Delivery SystemsPolymethacrylic AcidsPharmacokineticsimmune system diseasesOral administrationhemic and lymphatic diseasesmedicineAnimalsHumansPolyhydroxyethyl Methacrylatechemistry.chemical_classificationDrug CarriersGeneral Medicineoral deliveryRatsBioavailabilitySurgeryoral delivery; peptide delivery; calcitoninsurgical procedures operativechemistryCalcitoninSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPharmacodynamicsFemaleTurbidimetryCaco-2 CellsPeptidestherapeuticshuman activitiesPHEA oral delivery osteoporosis supramolecolar aggregates peptide almon calcitoninBiotechnology
researchProduct

Immune Therapy of Lympho-Hemopoietic Malignancies.

2017

Cancer ResearchImmunoconjugatesbusiness.industryAntibodies MonoclonalHematologyPrecursor Cell Lymphoblastic Leukemia-LymphomaImmune therapy03 medical and health sciencesHaematopoiesis0302 clinical medicineTreatment OutcomeOncologyLeukemia Myeloid030220 oncology & carcinogenesisHematologic NeoplasmsImmunologyAcute DiseaseMedicineHumans030212 general & internal medicineImmunotherapybusinessOncology research and treatment
researchProduct